Obesity

Reduced-frequency GLP-1 therapy sustains weight and metabolic benefits in obesity

March 9, 2026

A retrospective case series of 30 adults on semaglutide or tirzepatide found that shifting from weekly to reduced‑frequency dosing—often every other week—was associated with stable or continued modest weight loss over roughly 36 weeks. After plateauing at 74.1 kg on weekly therapy, patients averaged 72.4 kg during maintenance. Body fat continued to decline, skeletal muscle mass remained stable, and improvements in metabolic syndrome parameters were maintained.

Clinical takeaway: For patients who have reached a GLP‑1 plateau and seek lower treatment burden, structured dose de-escalation may help maintain weight and metabolic benefits while reducing injection frequency.

Source:

Wong M, et al. (2026, February 24). Obesity. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. https://pubmed.ncbi.nlm.nih.gov/41732031/